Sector News

Reuters: Apollo to bid for GlaxoSmithKline’s mature drugs

November 14, 2014
Life sciences
(Reuters) – Apollo Global Management is planning to bid for all GlaxoSmithKline’s mature drugs, joining an auction expected to value the business at more than $3 billion (1.19 billion pounds), according to four people familiar with the process.
 
The private equity firm, run by Leon Black, could change the dynamic of the auction because it is ready to buy all the products on offer, while other potential buyers are looking to acquire only certain regional businesses.
 
Apollo, GSK declined to comment.
 
BY SOPHIE SASSARD AND FREYA BERRY (Editing by Alex Smith)
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend